Contrasting of Capricor Therapeutics Inc. (CAPR) and Affimed N.V. (NASDAQ:AFMD)

Both Capricor Therapeutics Inc. (NASDAQ:CAPR) and Affimed N.V. (NASDAQ:AFMD) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Capricor Therapeutics Inc. 1.50M 7.92 14.04M -0.52 0.00
Affimed N.V. N/A 0.00 N/A -0.37 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Capricor Therapeutics Inc. and Affimed N.V.


Table 2 represents Capricor Therapeutics Inc. (NASDAQ:CAPR) and Affimed N.V. (NASDAQ:AFMD)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Capricor Therapeutics Inc. -936.00% -191.3% -118.7%
Affimed N.V. 0.00% -43.9% -26.7%

Risk & Volatility

Capricor Therapeutics Inc.’s 1.54 beta indicates that its volatility is 54.00% more volatile than that of Standard & Poor’s 500. Affimed N.V. on the other hand, has 3.08 beta which makes it 208.00% more volatile compared to Standard & Poor’s 500.


Capricor Therapeutics Inc. has a Current Ratio of 6.7 and a Quick Ratio of 6.7. Competitively, Affimed N.V.’s Current Ratio is 3 and has 3 Quick Ratio. Capricor Therapeutics Inc.’s better ability to pay short and long-term obligations than Affimed N.V.

Analyst Ratings

The table shown features the ratings and recommendations for Capricor Therapeutics Inc. and Affimed N.V.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Capricor Therapeutics Inc. 0 0 1 3.00
Affimed N.V. 0 0 1 3.00

The consensus target price of Capricor Therapeutics Inc. is $3.5, with potential upside of 2.04%. On the other hand, Affimed N.V.’s potential upside is 150.78% and its consensus target price is $8. The results from earlier shows that analysts belief suggest that Affimed N.V. seems more appealing than Capricor Therapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 5% of Capricor Therapeutics Inc. shares and 41.8% of Affimed N.V. shares. 32.93% are Capricor Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 8.15% of Affimed N.V.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Capricor Therapeutics Inc. -8.52% -30.63% -9.37% -60.34% -70.32% -5.17%
Affimed N.V. -3.92% -10.68% 0.29% -15.52% 49.13% 10.29%

For the past year Capricor Therapeutics Inc. has -5.17% weaker performance while Affimed N.V. has 10.29% stronger performance.


Affimed N.V. beats on 7 of the 10 factors Capricor Therapeutics Inc.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.